NASDAQ:ALZN Alzamend Neuro Q1 2027 Earnings Results & Report $1.34 -0.03 (-2.19%) Closing price 04:00 PM EasternExtended Trading$1.34 0.00 (0.00%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Alzamend Neuro missed analyst earnings expectations in its Q1 2027 results, released September 10, 2026. The company reported EPS of -$0.68 versus the -$0.56 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2027Report DateSeptember 10, 2026TimeBefore Market OpensConference Call7:00 AM ET Alzamend Neuro EPS ResultsActual EPS-$0.68Consensus EPS -$0.56Beat/MissMissed by -$0.12One Year Ago EPSN/AEPS Beat Rate4 of last 7 quartersAlzamend Neuro Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsAlzamend Neuro's Q2 2027 earnings is estimated for Tuesday, December 8, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, December 10, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Alzamend Neuro Q1 2027 Earnings FAQ Did Alzamend Neuro beat earnings estimates for Q1 2027? Alzamend Neuro (NASDAQ:ALZN) reported earnings of -$0.68 per share for Q1 2027, missing the consensus estimate of -$0.56. The report was announced on Thursday, September 10, 2026. When is Alzamend Neuro's next earnings date? Alzamend Neuro's next earnings date is estimated for Tuesday, December 8, 2026. MarketBeat tracks confirmed and estimated earnings dates for Alzamend Neuro on the company's earnings history page. Alzamend Neuro Earnings HeadlinesAlzamend Neuro (NASDAQ:ALZN) Shares Down 24% - Time to Sell?October 2, 2026 | americanbankingnews.comAlzamend Neuro Highlights Early AL001 Brain Lithium DataSeptember 29, 2026 | tipranks.comElon’s FINAL Warning? [US Dollar Collapse]On April 25, 2023, Elon Musk issued a stark warning about the future of the US dollar. A former Wall Street Journal personal finance expert says that prediction may now be unfolding, outlining five steps investors are weighing amid the shift.October 8 at 1:00 AM | International Living (Ad)Alzamend Regains Compliance With Nasdaq Equity RequirementSeptember 17, 2026 | rttnews.comAlzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DCAugust 20, 2026 | prnewswire.comAlzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, SpainAugust 18, 2026 | prnewswire.comSee More Alzamend Neuro Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Alzamend Neuro? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alzamend Neuro and other key companies, straight to your email. Email Address About Alzamend NeuroAlzamend Neuro (NASDAQ:ALZN) (NASDAQ: ALZN) is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative and psychiatric disorders. Its primary research efforts have centered on Alzheimer’s disease and related conditions, with additional potential applications in disorders such as bipolar disorder, post-traumatic stress disorder and major depressive disorder. The company’s lead product candidate, AL001, is based on a proprietary ionic cocrystal technology intended to deliver lithium in a formulation designed for the treatment of Alzheimer’s disease and other neurological conditions. Alzamend has also been developing AL002, an investigational immunotherapy candidate intended to target the underlying mechanisms associated with Alzheimer’s disease. Alzamend Neuro is headquartered in Atlanta, Georgia, and its activities have primarily involved preclinical research and clinical development conducted in the United States. As a development-stage biotechnology company, it does not have an established portfolio of commercially marketed products and remains dependent on the results of research, clinical trials and regulatory review.View Alzamend Neuro ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Levi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueSkydance Just Became a Media Giant—With an $80 Billion Debt LoadConstellation Brands Beat Earnings, But Beer Demand Is Still a ProblemTesla's EV Delivery Beat Is In, So What Happens Now?BigBear.ai Is Heavily Shorted—and Its Fundamentals Are Starting to ChangePenguin Solutions Is Soaring as AI Memory Demand Explodes Upcoming Earnings Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
